Laddar populära aktier...
Redeye leaves a comment on Faron’s recent pipeline update, suggesting that the company may look to expand its targeted indications to autoin...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report.
Redeye leaves a note following Faron’s announcement of positive feedback from its meeting with the FDA ahead of phase III trials.
Redeye provides a research update on Faron Pharmaceuticals following the outcome of the company’s recent share issue and clinical progress w...
Redeye leaves a comment following Faron’s announcement of a share issue raising up to EUR30.
Redeye leaves a comment following the first results published from the phase II part of the company’s ongoing BEXMAB study.
Redeye leaves a comment following Faron’s announcement of a change in its CEO position.
Redeye leaves a comment following Faron’s announcement of a conducted private placement raising EUR4.
Redeye leaves a comment following the recently announced updated data from the BEXMAB study with the company’s lead candidate bexmarilimab.
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual report, precarious financial situation, and...
Redeye leaves a comment following Faron’s announcement of binding commitments for convertible loans of a total amount of EUR3.
Redeye leaves a comment following the recent announcement by Faron stating that the company is in several Events of Default following possib...
Redeye leaves a comment following the recently announced updated data from the BEXMAB and MATINS studies with the company’s lead candidate b...
Redeye provides a comment following Faron’s announcement of the initiation of the phase II part of the ongoing BEXMAB study.
Redeye provides a short update following Faron’s recent clinical data update from the phase I/II BEXMAB study with its lead candidate, bexma...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent half-year report and clinical progress with lead c...
Redeye leaves a note following Faron’s recent study update from the phase I/II BEXMAB study with its lead candidate, bexmarilimab.
Redeye leaves a note following Faron’s additional study update from the phase I/II BEXMAB study with lead candidate Bexmarilimab.
Redeye is encouraged to learn that Faron has received positive FDA feedback and recommendations for the future development of lead candidate...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H2 report and clinical progress with lead candidat...
Redeye leaves a comment on Faron Pharmaceutical's recent private placement.
Redeye leaves a note following an announced trial update from the phase I/II BEXMAB study with lead candidate Bexmarilimab.
Faron has announced an interim trial update from the phase I/II BEXMAB study with lead candidate Bexmarilimab.
Redeye leaves a comment on Faron Pharmaceutical's recent capital raise.
Faron has announced top-line data on dose variation from the phase I/II MATINS study with lead candidate Bexmarilimab.
Redeye leaves a comment on the H1 report published by Faron Pharmaceuticals earlier today.
Redeye leaves a comment following Faron Pharmaceutical’s announcement earlier today of a placing of newly issued treasury shares.
Faron announced earlier today that the company’s New Drug (IND) application to initiate the phase I/II BEXMAB study with lead candidate Bexm...
Redeye initiates coverage of Faron Pharmaceuticals, a Finnish biotech company focused on developing next-generation immunotherapy, its three...
